Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (3,450)		$ (3,279)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1		2
Stock-based compensation	818		1,289
Loss on marketable equity securities	527		33
Amortization of premium related to convertible loans (Notes 8 and 12)	(1,257)		(2,149)
Accrued interest on convertible loans (Notes 8 and 12b)	45		56
Loss from extinguishment of convertible loans (Notes 8 and 12b)	977		1,709
Increase in license purchase obligation (Note 6)	150		150
Change in:
Other current assets	62		(86)
Other accounts payable	63		67
Net cash used in operating activities	(2,064)		(2,208)
Cash flows from investing activities
Purchase of property and equipment		[1]	(5)
Proceeds from sale of marketable equity securities			258
Net cash provided by investing activities		[1]	253
Cash flows from financing activities
Proceeds from issuance of shares and warrants (Note 11u)	550
Proceeds from issuance of shares with respect to exercise of PIPE Warrants and right for future investment			1,145
Proceeds from issuance of units consisting of Common Stock, Series A Preferred Stock and warrants (Note 12c)			3,915
Convertible loan repayment	(760)
Repayment of license purchase obligation	(150)		(150)
Net cash provided by (used in) financing activities	(360)		4,910
Effect of exchange rate change on cash, cash equivalents and restricted cash			1
Change in cash, cash equivalents and restricted cash	(2,424)		2,956
Cash, cash equivalents and restricted cash at the beginning of the year	3,183		227
Cash, cash equivalents and restricted cash at the end of the year	759		3,183
Supplemental disclosure of non-cash financing activities:
Increase in other current assets through equity			54
Deemed dividend with respect to the repurchase of right for future investment			292
Conversion of Preferred stock into Common Stock				[1]
Amount allocated to the repurchase of beneficial conversion feature in convertible loans			(1,918)
Amount allocated to the right for future investment - 2016 Loan upon 2018 Amendment			952
Amount allocated to the right for future investment- 2017 Loan upon 2018 Amendment			1,444
Ordinary shares issued through receipt of marketable securities (Note 11k)	765
Amount allocated to the repurchase right for existing right for future investment related to the 2016 Loan and the 2017 Loan - March 2019 Loan Amendment	(481)
Amounts that were allocated to the recognition of right for future investment - 2016 Loan - March 2019 Loan Amendment	256
Amounts that were allocated to the recognition of right for future investment - 2017 Loan - March 2019 Loan Amendment	386
Deemed dividends with respect to the repurchase of right for future investment - March 2019 Loan Amendment	104
Amount allocated to the repurchase right for existing right to future investment related to the 2016 Loan and the 2017 Loan - May 2019 Amendment	(152)
Amounts that were allocated to the right for future investment and warrants - 2016 Loan - May 2019 Amendment	381
Amounts that were allocated to the right for future investment and warrants - 2017 Loan - May 2019 Amendment	576
Deemed dividends with respect to the repurchase of right for future investment - May 2019 Amendment	81
Amount allocated to the 2016 Loan - March 2019 Loan Amendment	729
Amount allocated to the 2017 Loan - March 2019 Loan Amendment	1,037
Amount allocated to the 2016 Loan - May 2019 Amendment	634
Amount allocated to the 2017 Loan - May 2019 Amendment	922
Repayment of convertible loans through Common Stock	760
Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants	267
Sell of Cannabics's shares through a broker	$ 260

[1] Representing amount less than $1